statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	456
CN - Cina	123
IE - Irlanda	99
SG - Singapore	78
RU - Federazione Russa	47
DE - Germania	44
VN - Vietnam	44
BR - Brasile	42
HK - Hong Kong	42
FI - Finlandia	22
CA - Canada	21
IT - Italia	19
ZA - Sudafrica	15
IN - India	14
FR - Francia	13
SE - Svezia	8
GB - Regno Unito	7
BD - Bangladesh	6
MX - Messico	5
NL - Olanda	5
PL - Polonia	4
AE - Emirati Arabi Uniti	3
AT - Austria	3
ES - Italia	3
IQ - Iraq	3
JP - Giappone	3
KE - Kenya	3
MA - Marocco	3
AR - Argentina	2
BG - Bulgaria	2
ID - Indonesia	2
MY - Malesia	2
PE - Perù	2
PH - Filippine	2
PK - Pakistan	2
AU - Australia	1
BA - Bosnia-Erzegovina	1
CL - Cile	1
CO - Colombia	1
ET - Etiopia	1
GA - Gabon	1
GD - Grenada	1
GE - Georgia	1
GR - Grecia	1
IL - Israele	1
JO - Giordania	1
LB - Libano	1
LK - Sri Lanka	1
LT - Lituania	1
LV - Lettonia	1
MD - Moldavia	1
MU - Mauritius	1
NI - Nicaragua	1
QA - Qatar	1
RO - Romania	1
SA - Arabia Saudita	1
SC - Seychelles	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
TM - Turkmenistan	1
UA - Ucraina	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.177

Nome	#
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms	154
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin	128
Diagnosis and management of prefibrotic myelofibrosis.	111
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.	107
Facing erythrocytosis: Results of an international physician survey.	102
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.	99
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.	92
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.	92
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms	80
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera.	78
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.	78
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.	71
Totale	1.192

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	62	0	0	10	2	3	3	1	3	3	1	9	27
2022/2023	210	24	12	5	9	15	15	0	13	106	4	6	1
2023/2024	105	16	21	6	5	6	35	0	8	3	1	2	2
2024/2025	229	8	14	6	1	0	16	14	18	66	5	32	49
2025/2026	493	41	15	47	49	50	21	117	30	58	30	11	24
Totale													1.192